post

Current Clinical Trials

The MU-Veterinary Health Center (VHC) is currently seeking patients for enrollment in funded oncology clinical trials. Study goals and suitability for each patient are discussed in detail with the clients prior to enrollment. Although clinical trial enrollment may not be the best option for all patients, in many cases, clinical trial participation provides the opportunity to receive novel, cutting-edge therapies free of charge or at a reduced cost and may facilitate treatment of pets where it would not otherwise be possible due to financial constraints or lack of other therapy options. Criteria for enrollment are outlined for each tumor type below. Please direct referrals or questions to Debbie Tate, RVT, VTS (clinical trials coordinator) or the Oncology Clinical Trials Service at 573-882-7821.

Learn about opportunities to participate in clinical trials at other institutions at vetcancertrials.org.

Autologous Melanoma and Apocrine Gland Adenocarcinoma of the Anal Sac Vaccine Study

This is a prospective single arm efficacy trial of adjuvanted autologous tumor vaccine. Tumor specimens will be collected surgically. Treated cells will be aliquoted for re-injection into the patient with adjuvants added.

Criteria:

  • Histologic or cytologic confirmed oral melanoma or apocrine gland adenocarcinoma of anal sac (AGASACA)
  • CBC, Chemistry panel, UA, FNA of draining lymph node, thoracic radiographs, +/- abdominal U/S
  • Adequate renal, hepatic and hematologic parameters.
  • Prior chemotherapy allowable with a 3 week washout.
  • Must weigh at least 5 kg
  • No significant co-morbidities
  • Performance score of 0 or 1
  • MUST have at least 2 cm of tumor present at presentation

Exclusion:

  • Prior radiation therapy or Oncept vaccination
  • Metastasis to distant location
  • Tumor < 2 cm
  • Immunosuppressive therapy

Therapy:

  • Surgical resection of tumor at VHC
  • Subcutaneous injection of vaccine every 2 weeks for 4 treatments.
  • Immune blood collection prior to each vaccination.
  • Periodic rechecks following vaccination

Benefit:

  • Owner to receive $1000.00 towards cost of surgery.
  • Owner to receive vaccinations, office calls, scheduled follow-up radiographs and cytology at no charge.
  • Initial staging cost are owner’s financial responsibility.

       Contact Faculty Person: Dr. Jeff Bryan


Use of CT/18F-FDG PET imaging in the prognosis and pathologic evaluation of soft tissue sarcomas

The aim of the project is to determine the biologic behavior of sarcomas on PET/CT and correlate it with a more traditional histological grading system. This will be accomplished by using a well-established methodology which utilizes 18F-Fluorodeoxglucose Positron Emission Tomography (18F-FDG-PET). The hypothesis is that 18F-FDG-PET will have variable glycolytic activity depending upon tumor grade and that the initial standardized uptake values (SUV) can be associated with patient prognosis and survival.

Criteria:

  • Histologic or cytologic (if consistent with clinical presentation) confirmed soft tissue sarcoma
  • CBC, Chemistry panel, UA, FNA of draining lymph node, thoracic radiographs, +/- abdominal U/S
  • Adequate renal, hepatic and hematologic parameters.
  • No significant co-morbidities
  • Definitive surgery performed at UMC Veterinary Health Center

Exclusion:

  • Recurrent sarcoma
  • Prior chemotherapy or radiation therapy
  • Tumor < 10 mm

Therapy:

  • CT/18F-FDG-PET scan.
  • Definitive surgery performed at UMC Veterinary Health Center
  • Histopathologic evaluation of tumor.

Benefit:

  • Study to pay $1000.00 towards CT/18F-FDG-PET, plus $500.00 towards surgery. For total of $1500.00

       Contact Faculty Person: Dr. Jeff Bryan, and Dr. Emily Miller


CTI-52010

CTI-52010 is a new nanoparticle taxane drug that has been developed to avoid the allergic reactions of earlier taxanes. It has already been shown to be safe in normal dogs. This clinical trial will refine the proper drug dosage for dogs with cancer and determine whether there is evidence of efficacy when administered subcutaneously.

Criteria:

Any tumor (except osteosarcoma, lymphoma, prostate carcinoma) confirmed by histopathology or cytology. Tumor must be at least 2 cm in length-must have tumor present at enrollment

  • Normal CBC, renal and liver function, UA and thoracic radiographs at first visit.
  • Washout from last chemotherapy- time depends upon drug
  • Patient must weigh over 5 kgs

Therapy:

  • One subcutaneous injection of CTI-52010
  • Pharmacokinetic samples taken at various intervals over 24 hours post injection and Days 7 & 14
  • CBC, chemistry panel, UA, on days 0, 7, 14, 21, 28. Thoracic radiographs every 2 months.

 Benefit:

  • Once enrolled study is fully funded. Treatment includes: free drug and drug administration, hospitalization for 1st night, blood work, and office calls.
  • Initial staging is owner’s responsibility.

Contact Faculty Person: Dr. Kim Selting


Canine Cachexia Study

The true prevalence of cachexia in canine patients has not been determined, due in part to euthanasia when a pet’s quality of life declines and weight loss ensues. The objectives for this study are to determine toxicity, including cardiovascular effects of the final drug candidate of MC4 peptide receptor antagonist and to determine preliminary efficacy of MC4 peptide receptor antagonist in dogs with cachexia.

Criteria:

  • History of 5% or greater with loss within past three months
  • Radiation and chemotherapy allowed at clinician discretion
  • Washout of 2 days required for appetite stimulants.
  • CBC, chemistry panel, UA, and abdominal ultrasound within 14 days of enrollment
  • Corticosteriod use allowed if > 14 days prior to enrollment

      Exclusion:

  • Concurrent CHF, cardiac arrhythmias (related to bradycardia), dilated cardiomyopathy, azotemia, renal failure or liver dysfunction
  • Cancer of the GI tract; esophagus, stomach or intestines
  • Use of appetite stimulants

Therapy:

  • Initial visit-Blood work, abdominal ultrasound, 24 hour holter monitor, blood pressure.
  • Subsequent visit: Photos, followed by subcutaneous administration of MC4 peptide receptor antagonist, 24 hr PK sampling post drug administration.
  • Daily subcutaneous administration of MC4 peptide receptor antagonist by owner.
  • CBC, chemistry panel, UA week 2 and week 4
  • Holter monitor at week 4
  • Blood pressure checked pretreatment and at week 4.
  • Owner to complete daily diary

Benefit: Owner to pay initial office visit and bloodwork. Study covers abdominal ultrasound, cost of monitoring and treatment.     

Contact Faculty Person: Dr. Sandra Bechtel


COTC021-OSA-SOC + Rapamycin

COTC021-OSA-SOC + Rapamycin seeks to evaluate the safety and effectiveness of Standard of Care therapy, with adjuvant rapamycin administration. Standard of Care is defined as amputation of the affected limb, followed by four doses of carboplatin given every three weeks. Dogs will be randomized to either COTC021 or COTC022 at the start of therapy, which will determine the treatment prescribed.

Criteria:

  • Appendicular osteosarcoma confirmed by histopathology or cytology
  • Normal CBC, chemistry panel, UA, abdominal ultrasound, and thoracic radiographs within 10 days of amputation at MU-VHC. All staging must be done at MU-VHC.
  • Patient must weigh over 25 kgs
  • No prior chemotherapy, radiation therapy or bisphosphonates
  • NSAIDS, gabapentin, tramadol allowed prior to and during study
  • Favorable performance status

Therapy:

  • Surgical amputation of affected limb at MU-VHC
  • First carboplatin infusion within 10-14 days of surgery, then every 3 weeks for total of 4 doses
  • Oral rapamycin to start within 7 days of week 15 visit- Monday –Thursday administration
  • Return visits on Days 11, and 25, then monthly of every rapamycin cycle for overnight pharmacokinetics.

 Benefit:

  • Owner to pay initial office call, staging and post chemo CBC’s.
  • Owner to receive $1000.00 credit towards amputation at the MU-VHC.
  • Once enrolled study is mostly funded. Study covers following costs: drug and drug administration, blood work at chemo visits, imaging (radiographs) and VHC office calls.

Contact Faculty Person: Dr. Brian Flesner


COTC022-OSA-SOC

COTC022-OSA-SOC seeks to evaluate the safety and effectiveness of Standard of Care therapy, with adjuvant rapamycin administration. Standard of Care is defined as amputation of the affected limb, followed by four doses of carboplatin given every three weeks. Dogs will be randomized to either COTC021 or COTC022 at the start of therapy, which will determine the treatment prescribed.

Criteria:

  • Appendicular osteosarcoma confirmed by histopathology or cytology
  • Normal CBC, chemistry panel, UA, abdominal ultrasound, and thoracic radiographs within 10 days of amputation at MU-VHC. All staging must be done at MU-VHC.
  • Patient must weigh over 25 kgs
  • No prior chemotherapy, radiation therapy or bisphosphonates
  • NSAIDS, gabapentin, tramadol ok prior to and during study
  • Favorable performance status

Therapy:

  • Surgical amputation of affected limb at MU-VHC
  • First carboplatin infusion within 10-14 days of surgery, then every 3 weeks for total of 4 doses

Benefit:

  • Owner to pay initial office call, staging and post chemo CBC’s.
  • Owner to receive $1000.00 credit towards amputation at the MU-VHC.
  • Once enrolled study is mostly funded. Study covers following costs: drug and drug administration, blood work at chemo visits, imaging (radiographs) and VHC office calls.

Contact Faculty Person: Dr. Brian Flesner

Safety and Efficacy of Surgery and ECI-OSA-1 as Treatments for Newly Diagnosed Osteosarcomas in Dogs Study

This single armed Phase I/IIa clinical trial is designed to obtain a preliminary determination of whether ECI-OSA-1 (cancer antigen-specific T cells) significantly improves clinical outcomes when used to treat newly diagnosed surgically resected osteosarcoma. ECI-OSA-1 is combined with surgery and the outcomes are compared to historical control data obtained using surgery alone and surgery with chemotherapy.

Criteria:

  • Histologic or cytologic confirmed osteosarcoma
  • CBC, Chemistry panel, UA, thoracic radiographs, bone scan
  • Adequate renal, hepatic and hematologic parameters.
  • No evidence of metastasis on radiographs or bone scan
  • No significant co-morbidities
  • Must be appendicular osteosarcoma
  • Must weigh greater than 25 kg and a good candidate for limb amputation

Exclusion:

  • Currently receiving glucocorticoids or other immunosuppressive agent
  • Second malignancy that is not in remission
  • Patient is receiving or has received treatment other than surgery for their tumor

Therapy:

  • Amputation of affected limb at VHC
  • Intradermal injection of vaccine one, two and three weeks post amputation.
  • DTH-vaccination #3 and at apheresis
  • Blood collection week 5 via apheresis
  • Infusion of activated T cells at week 6
  • Every other day Il-2 injections one-two days post T-cell infusion, +/- one day
  • Follow up CBC, chemistry panel, urinalysis, thoracic radiographs at week 9 post IL-2 injections

Benefit:

  • Owner to pay initial office visit and staging, except bone scan. Once enrolled study is fully funded, includes bone scan, radiographs, blood work, amputation, vaccinations, blood collection, T-cell infusion, Il-2 injections and follow-up.

       Contact Faculty Person: Dr Jeffrey Bryan

Golden Retrievers with New Diagnosis of Lymphoma Needed for Biopsy Study

Veterinarians at the University of Missouri, Colorado State University and Texas A&M University seek Golden Retrievers with a new diagnosis of lymphoma for an important study of lymphoma. Golden Retrievers with lymphoma that have not been treated with chemotherapy or prednisone who do not have elevated blood calcium may receive a diagnostic biopsy and flow cytometry analysis of their tumor at no cost for the procedure. Dogs must be evaluated at one of the participating Universities. This study seeks to classify B cell lymphomas more thoroughly for important clinical decision-making. It also seeks the underlying alterations in the tumor cells to provide clues for cause and for new therapy approaches. To schedule an appointment at the University of Missouri, please call (573) 882-7821. Standard consultation fees apply, but eligible dogs will receive biopsy and flow cytometry at no cost to the client. This trial is funded by the Canine Health Foundation and Morris Animal Foundation.